KHẢO SÁT SỰ THAY ĐỔI NỒNG ĐỘ HCV CORE ANTIGEN (HCVCAG) TRONG QUÁ TRÌNH ĐIỀU TRỊ THUỐC DAAS Ở NGƯỜI BỆNH VIÊM GAN VI RÚT C

Abstract

Objective: Observing changes in HCVcAg kinetics during DAAs treatment in patients with hepatitis C virus. Subjects   and methods: A  cross sectional  descriptive  study use of convenience sampling method was  performed  on 36 patients  ≥16 years old diagnosed with hepatitis C treated with DAAs and monitored at the Center for Tropical Diseases - Bach Mai Hospital. HCVcAg, HCV RNA and other hematological biochemical tests were evaluated at the following times: before, 4 weeks, 12 weeks of treatment and after 3-6 months upon completion of treatment. Results and conclusions: The level of HCVcAg was 5260.54 ± 4421.98 fmol/L. HCVcAg levels decreased rapidly during DAAs treatment. At 4 weeks, 30/33 cases did not detect HCVcAg, at 12 weeks and after the end of treatment, no case detected HCVcAg.